Lilly, Bristol Drug Dilution Settlement May Increase Focus On “Gray Market”
Executive Summary
The size of settlement payments made by Lilly and Bristol-Myers Squibb in the Kansas City drug dilution case is the latest warning to manufacturers that they may need to become more aggressive in policing the so-called "gray market" for pharmaceuticals